Apo-B/apo-AI ratio: A better discriminator of coronary artery disease risk than other conventional lipid ratios in Indian patients with acute myocardial infarction

Acta Cardiologica

Volumn 63, Issue 6, 2008, Pages 749-755

  Goswami, Binita ^a   Rajappa, Medha ^b   Mallika, Venkatesan ^c   Kumar, Suresh ^a   Shukla, Deepak Kumar ^d  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c G B PANT HOSPITAL   (India)

^d INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Apolipoprotein B 100; Apolipoprotein AI; Coronary artery disease; High density lipoprotein; Low density lipoprotein

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY; ENZYME CHEMISTRY; FEMALE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK REDUCTION; TURBIDIMETRY;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; COMORBIDITY; CORONARY ARTERY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK ASSESSMENT;

EID: 58049193621     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.63.6.2033393     Document Type: Article

References (42)

1. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 49: 1498-504.
2. Achari V, Thakur AK. Association of major modifiable risk factors among patients with CAD - a retrospective analysis. J Assoc Phys India 2004; 52: 103-8.
3. Mckeigne PM, Miller GJ, Marmot MG. Coronary artery disease in south Asians overseas: a review. J Clin Epidemiol 1989; 41: 597-8.
4. Enas EA, Dhawan J, Petkar S. Coronary artery disease in Asian Indians: Lessons learned so far and the role of Lp(a). Indian Heart J 1997; 49: 25-34.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mac-Farlane PW. Prevention of coronary heart disease with prevastatin in men with hypercholesterolemia. West Scotland Coronary Prevention study group. N Engl J Med 1995; 333: 1301-7.
6. The BIP study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease - the Benzafibrate Infarction prevention (BIP) study. Circulation 2000; 102: 21-7.
7. Genest JJ, McNamara JR, Ordovas JM, Jenner JL, Silberman SR. Anderson KM. Lipoprotein cholesterol, apolipoprotein AI and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992; 19: 792-802.
8. Rajappa M, Sridhar MG, Balachander J, Sethuraman KR. Lipoprotein (a) and comprehensive lipid tetrad index as a marker for coronary artery disease in NIDDM patients in South India. Clin Chim Acta 2006; 372: 70-5.
9. Snidermann AD, Pedersen T, Jekshus J. Putting low density lipoproteins at center stage in atherogenesis. Am J Cardiol 1997; 79: 64-7.
10. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Kurds RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917-21.
11. Sniderman AD, Cianflone K. Measurement of apoproteins: Time to improve the diagnosis and treatment of the atherogenic dyslipidemias. Clin Chem 1996; 42: 489-91.
12. Mallika V, Goswami B, Rajappa M. Atherosclerosis-pathophysiology and role of novel risk factors: a clinico-biochemical perspective. Angiology 2007; 58: 513-22.
13. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Non-fasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged men. Arterioscler Thromb Vasc Biol 2002; 22: 1918-1923.
14. Grundy SM. Cholesterol-lowering clinical trials: a historical perspective. In: Grundy SM, ed. Cholesterol lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker, 2000; p. 1-44.
15. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Junger I, Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777-80.
16. Maziar R, Farbod R, Sima A, Shahryar K, Mohamad N, Fereidoun A. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis 2002; 162: 381-9.
17. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
18. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95: 69-75.
19. Schaefer EJ. Familial lipoprotein disorders and premature coronary artery disease. Med Clin North Am 1994; 78: 21-39.
20. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Usefulness of total cholesterol to high-density lipoprotein cholesterol ratio in predicting angiographic coronary artery disease in women. Am J Cardiol 1991; 68: 1646-50.
21. Castelli WP, Andersen K, Wilson PWF, Levy D. Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol 1992; 2: 23-8.
22. Kinosian B, Glick H, Preiss L, Puder KL. Cholesterol and coronary heart disease: predicting risks in men by changes in levels and ratios. J Investig Med 1995; 43: 443-50.
23. Criqui MH, Golomb BA. Epidemiologic aspects of lipid abnormalities. Am J Med 1998; 105: 48S-57S.
24. Alpert JS, Thygesen K, Antman E, Barband JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Comniittee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-69.
25. Schillinger M, Exner M, Mlekusch W, Sabeti S, Amighi J, Nikowitsch R, Timmel E, Kickinger B, Minar C, Pones M, Lalouschek W, Rumpold H, Maurer G, Wagner O, Minar E. Inflammation and Carotid Artery-Risk for Atherosclerosis study (ICARAS). Circulation 2005; 111: 2203-9.
26. American Diabetic Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-201.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
28. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-445.
29. Kukita H, Hamada M, Hiwada K, Kokbu T. Clinical significance of measurements of serum apolipoprotein A-I, A-II and B in hypertriglyceridemic male patients with and without coronary artery disease. Atherosclerosis 1985; 55: 143-9.
30. Lamarche B, Despres JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischernic heart disease (prospective results from the Quebec Cardiovascular study). Am J Cardiol 1995; 75: 1189-95.
31. Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO. Association of coronary atherosclerosis with hyperapobetalipoproteinernia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]. Proc Natl Acad Sci USA 1980; 77: 604-8.
32. Sniderman AD. Counterpoint to (measure apo) B or not to (measure apo) B: a critique of modem medical decision making. Clin Chem 1997; 43: 1310-4.
33. Williams KJ, Tabas I. The response-to-injury hypothesis of early atherogenesis. Arterioscler Thromb Vas Biol 1995; 15: 551-61.
34. Tribble DL, Holi LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992; 93: 189-99.
35. Teng B, Sniderman A, Krauss RM, Kwiterovich PO, Milne RW, Marcel YL. Modulation of apolipoprotein-B antigenic determinations in human low density lipoprotein subclasses. J Biol Chem 1985; 260: 5067-72.
36. Teng B, Sniderman AD, Soutar AK, Thompson GR. Metabolic basis of hyperapobetalipoproteinernia. Turnover of apolipoprotein-B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest 1986; 77: 663-72.
37. Kim HK, Chang Sa, Chol EK, Int YJ, Kim HS, Sohn DW, On BH, Lee MM, Park YB, Choi YS. Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population. Int J Cardiol 2005; 101: 435-40.
38. Jadhav UM, Kadam NN. Apolipoproteins: Correlation with carotid intima media thickness and coronary artery diseases. J Assoc Phys India 2004; 52: 370-5.
39. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study); case-control study. Lancet 2004; 364: 937-52.
40. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, De Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ ten-country panel. J Intern Med 2006; 259: 247-58.
41. Sniderman AD, Kiss RS. The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysis. Curr Atheroscler Rep 2007; 9: 261-5.
42. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006; 259: 493-519.